Skip to content

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

Deep-learning Derived Chest Computed Tomography (CT) Biomarkers as Prognostic Predictors in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06472362
Enrollment
1000
Registered
2024-06-25
Start date
2024-11-01
Completion date
2026-03-31
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Brief summary

The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.

Detailed description

Interstitial lung disease (ILD or lung fibrosis=stiffening of the lungs by scar tissue) develops in over half of patients with systemic sclerosis (SSc). Whilst ILD remains stable in some patients, at least a third have progressively increasing fibrosis. There is a pressing need for accurate indicators that identify a) patients at higher risk of progression, needing immediate treatment to prevent further irreversible ILD; and b) patients at lower risk, not needing treatment. In this study the prognostic potential and accuracy of machine-learning derived biomarkers to evaluate abnormalities that are difficult to quantify visually will be investigated. Whether novel high resolution computed tomography (HRCT) imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline can predict ILD progression, vasculopathy development, and survival will be investigated in a cohort of approximately 1,000 SSc-ILD patients. The algorithm scores will be evaluated against survival using Cox proportional hazards modelling, while mixed effects model analysis will be used to assess links with change in lung function: forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), and carbon monoxide transfer coefficient (Kco). The airway algorithm measuring traction bronchiectasis (dilatation of the airways due to surrounding fibrosis) may predict worsening of FVC, reflective of ILD progression. The vessel algorithm may predict decline in KCO, a marker of pulmonary vascular involvement. Exploratory analyses evaluating change in HRCT fibrosis extent over time for patients with repeat HRCTs will also be performed, and whether composite outcomes of change in HRCT and lung function variables improve long term outcome prediction and pave the way to their use in clinical trials and routine clinical use. Patients with trivial changes on CT will also be included to assess for very early changes that could be predictive of future decline. These algorithms will be combined with the findings of our previous study, which suggest that a certain type of pattern on CT called UIP predicts shorter survival.

Interventions

DIAGNOSTIC_TESTHRCT biomarkers

HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis

Sponsors

Imperial College London
CollaboratorOTHER
Royal Free and University College Medical School
CollaboratorOTHER
The Leeds Teaching Hospitals NHS Trust
CollaboratorOTHER
Hannover Medical School
CollaboratorOTHER
University of Siena
CollaboratorOTHER
Università Politecnica delle Marche
CollaboratorOTHER
Azienda Ospedaliero Universitaria di Sassari
CollaboratorOTHER
Bichat Hospital
CollaboratorOTHER
Royal Brompton & Harefield NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* diagnosed with SSc * ≥18 years old * HRCT between 01/01/1990 and 31/12/2019

Exclusion criteria

* Patients who do not have SSc * \<18 years old * lack of availability of HRCT imaging data

Design outcomes

Primary

MeasureTime frameDescription
Survival15 yearsTransplant-free survival
Pulmonary hypertension15 yearsDevelopment of pulmonary hypertension
Decline in FVC15 yearsChange in lung function measure FVC
Decline in DLCO15 yearsChange in lung function measure DLCO
Decline in KCO15 yearsChange in lung function measure KCO

Countries

France, Germany, Italy, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026